Clinical efficacy and safety of statins in managing cardiovascular risk

References

• Alsheikh-AliAAAmbroseMSKuvinJTThe safety of rosuvastatin as used in common clinical practice: a postmarketing analysisCirculation20051113051715911706
   PubMed Web of Science ®Google Scholar
• Alsheikh-AliAMaddukuriPVHanHEffect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trialsJ Am Coll Cardiol2007504091817662392
   PubMed Web of Science ®Google Scholar
• ArcaMarcelloAtorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndromeDrugs200767435417910520
   PubMed Web of Science ®Google Scholar
• ArmitageJThe safety of statins in clinical practiceLancet200766 Epub ahead of print
   PubMed Web of Science ®Google Scholar
• [ALLHAT] The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupMajor outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual careJAMA20022882998300712479764
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536612677816214597
   PubMed Web of Science ®Google Scholar
• BallantyneCMWeissRMoccettiTEfficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)Am J Cardiol2007996738017317370
   PubMed Web of Science ®Google Scholar
• BarterPGottoAMLaRosaJCHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsN Engl J Med200735713011017898099
   PubMed Web of Science ®Google Scholar
• BaysHStatin safety: an overview and assessment of the data - 2005Am J Cardiol2006976C26C
   PubMed Web of Science ®Google Scholar
• BaysHOseLFraserNA multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemiaClin Ther20042617587315639688
   PubMed Web of Science ®Google Scholar
• BlumenthalRSKapurNKCan a potent statin actually regress coronary atherosclerosis?JAMA20062951583416533937
   PubMed Web of Science ®Google Scholar
• BradfordRHShearCLChremosANExpanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-upAm J Cardiol199474667737942524
   PubMed Web of Science ®Google Scholar
• BrewerHBBenefit-risk assessment of Rosuvastatin 10 to 40 milligramsAm J Cardiol20039223K29K
   PubMed Web of Science ®Google Scholar
• BrownWVBaysHEHassmanDREfficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trialAm Heart J200214410364312486428
   PubMed Web of Science ®Google Scholar
• BullanoMFWertzDAYangGWEffect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care settingPharmacotherapy2006264697816553504
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350149550415007110
   PubMed Web of Science ®Google Scholar
• CarbonellTFreireEBinding thermodynamics of statins to HMG-CoA reductaseBiochemistry200544117414816128575
   PubMed Web of Science ®Google Scholar
• CohenDEAnaniaFAChalasaniNAn assessment of statin safety by hepatologistsAm J Cardiol200697suppl 8A77C81C16377288
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) : multicentre randomised placebo-controlled trialLancet20043646859615325833
   PubMed Web of Science ®Google Scholar
• CrouseJRGrobbeeDEO’learyDHMeasuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR studyCardiovasc Drugs Ther200418231815229392
   PubMed Web of Science ®Google Scholar
• CrouseJR3rdRaichlenJSRileyWAMETEOR Study GroupEffect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR TrialJAMA200729713445317384434
   PubMed Web of Science ®Google Scholar
• DavidsonMHDifferences between clinical trial efficacy and real-world effectivenessAm J Manag Care20061215 SupplS4051117112328
   PubMed Web of Science ®Google Scholar
• DavidsonMHClarkJAGlassLMStatin safety: an appraisal from the adverse event reporting systemAm J Cardiol2006978A32C43C
   PubMed Web of Science ®Google Scholar
• DavidsonMHMakiKCPearsonTAResults of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendationsAm J Cardiol2005965566316098311
   PubMed Web of Science ®Google Scholar
• DavignonJLaaksonenRLow-density lipoprotein-independent effects of statinsCurr Opin Lipidol1999105435910680049
   PubMed Web of Science ®Google Scholar
• DeedwaniaPGuptaMSteinMFirst large randomized trial of a statin therapy in south asian patients at risk for coronary heart disease: The IRIS trialAtheroscler Suppl2006206161
   Google Scholar
• DownsJRClearfieldMWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPSJAMA19982791615229613910
   PubMed Web of Science ®Google Scholar
• EndoAThe origin of the statinsAtheroscler Suppl200451253015531285
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsSummary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA19932693015238501844
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA200128524869711368702
   PubMed Web of Science ®Google Scholar
• FerdinandKCClarkLTWatsonKEComparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trialAm J Cardiol2006972293516442368
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationFDA advisory committee meeting briefing document NDA 21-366 for the use of Crestor2006 Accessed July 7, 2006. URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3968B1_02_A-FDA-Clinical%20Review.pdf
   Google Scholar
• GoettschWGHeintjesEMKasteleinJJResults from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO studyPharmacoepidemiol Drug Saf2006154354316761304
   PubMed Web of Science ®Google Scholar
• GrundySMThe issue of statin safety: where do we stand?Circulation200511130161915911705
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesJ Am Coll Cardiol2004447203215358046
   PubMed Web of Science ®Google Scholar
• HatsukamiTZhaoXQKraissLWAssessment of rosuvastatin treatment on carotid atherosclerosis in moderate hypercholesterolemic subjects using magnetic resonance imagingEur Heart J200526Abstract suppl626
   Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• HoldaasHFellstromBJardineAGEffect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre randomized placebo-controlled trialLancet200336120243112814712
   PubMed Web of Science ®Google Scholar
• HoldgateGAWardWHMcTaggertFMolecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatinBiochem Soc Trans2003315283112773150
   PubMed Web of Science ®Google Scholar
• IstvanESDesienhoferJStructural mechanism for statin inhibition of HMG-CoA reductaseScience20012921160411349148
   PubMed Web of Science ®Google Scholar
• JonesPInternational Symposium on Atherosclerosis2006618-22Rome, Italy
   Google Scholar
• JonesPKafonekSLauroraIComparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)Am J Cardiol19988158279514454
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHSteinEAComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)Am J Cardiol2003921526012860216
   PubMed Web of Science ®Google Scholar
• KasiskeBLWannerCO’NeillWCAn assessment of statin safety by nephrologistsAm J Cardiol200697suppl 8A82C85C
   PubMed Web of Science ®Google Scholar
• KhushKKWatersDDBittnerVEffect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) studyCirculation20071155768317261662
   PubMed Web of Science ®Google Scholar
• KrumHTonkinAThe Rosuvastatin Impact on Ventricular Remodelling Cytokines and Neurohormones (UNIVERSE) study [Abstract]J Am Coll Cardiol20062661A62A
   Google Scholar
• LaRosaJCGrundySMKasteleinJJSafety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)Am J Cardiol20071007475217719314
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med200535214253515755765
   PubMed Web of Science ®Google Scholar
• LawMRudnickaARStatin safety: a systematic reviewAm J Cardiol20069752C60C
   PubMed Web of Science ®Google Scholar
• [LIPID] The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med19983391349579841303
   PubMed Web of Science ®Google Scholar
• LlorettRHaffnerSYcasJSteinMfor the STARSHIP Study GroupLipid-lowering results from the first large-scale trial of statin therap in Hispanic-American patients with hypercholesterolemia: STARSHIPJ Am Coll Cardiol200626349A50A Abstract
   Google Scholar
• McAfeeATMingEESeegerJDThe comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapyPharmacoepidemiol Drug Saf2006154445316761308
   PubMed Web of Science ®Google Scholar
• McKenneyJMDavidsonMHJacobsonTAFinal conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task ForceAm J Cardiol20069789C94C
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJSipahiIEffect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trialJAMA200629515566516533939
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMSchoenhagenPEffect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trialJAMA200429110718014996776
   PubMed Web of Science ®Google Scholar
• OhsfeldtRLGandhiSKFoxKMEffectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practiceAm J Manag Care20061215 SupplS4122317112329
   PubMed Web of Science ®Google Scholar
• OlssonAGIstadHLuurilaOEffects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemiaAm Heart J200214410445112486429
   PubMed Web of Science ®Google Scholar
• PearsonTALauroraIChuHThe lipid treatment assessment project (L-TAP) : a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goalsArch Intern Med20001604596710695686
   PubMed Web of Science ®Google Scholar
• PedersenTRFaergemanOKasteleinJJHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialJAMA200529424374516287954
   PubMed Web of Science ®Google Scholar
• RainaAPickeringTShimboDStatin use in heart failure – A cause for concern?Am Heart J2006152394916824830
   PubMed Web of Science ®Google Scholar
• RidkerPMJUPITER study groupRosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trialCirculation20031082292714609996
   PubMed Web of Science ®Google Scholar
• RobinsonJGSmithBMaheshwariNPleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysisJ Am Coll Cardiol20054618556216286171
   PubMed Web of Science ®Google Scholar
• SacksFMPfefferMAMoyeLAThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levelsN Engl J Med1996335100198801446
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study GroupRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet1994344138397968073
   PubMed Web of Science ®Google Scholar
• SchneckDWKnoppRHBallantyneCMComparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial diseaseAm J Cardiol200391334112505568
   PubMed Web of Science ®Google Scholar
• SchwartzGGOlssonAGEzekowitzMDEffects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study – a randomized controlled trialJAMA2001285171118S11277825
   PubMed Web of Science ®Google Scholar
• SchusterHThe GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY ProgrammeExpert Rev Cardiovasc Ther200751779317338663
   PubMedGoogle Scholar
• SerruysPWde FeyterPMacayaCFluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trialJAMA200228732152212076217
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) : a multicentre randomised controlled trialLancet200336111495812686036
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemiaN Engl J Med1995333130177566020
   PubMed Web of Science ®Google Scholar
• ShepherdJBlauwGJMurphyMBPravastatin in elderly individuals at risk of vascular disease (PROSPER) : a randomised controlled trialLancet200236016233012457784
   PubMed Web of Science ®Google Scholar
• SmildeTJvan WissenSWollersheimHEffect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP) : a prospective, randomised, double-blind trialLancet20013575778111558482
   PubMed Web of Science ®Google Scholar
• SteinEStenderSMataPfor the Ezetimibe Study GroupAchieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatinAm Heart J20041484475515389231
   PubMed Web of Science ®Google Scholar
• TaylorAJKentSMFlahertyPJARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thicknessCirculation200210620556012379573
   PubMed Web of Science ®Google Scholar
• ThompsonPDClarksonPMRosensonRSAn assessment of statin safety by muscle expertsAm J Cardiol20069769C76C
   PubMed Web of Science ®Google Scholar
• TuomilehtoJLeiterLAKallendDA review of the efficacy of rosuvastatin in patients with type 2 diabetesInt J Clin Pract Suppl2004143304016035394
   PubMedGoogle Scholar
• VaughanCJGottoAMJrUpdate on statins: 2003Circulation20041108869215313959
   PubMed Web of Science ®Google Scholar
• VidtDGHarrisSMcTaggartFEffect of short-term rosuvastatin treatment on estimated glomerular filtration rateAm J Cardiol2006971602616728222
   PubMed Web of Science ®Google Scholar
• ZipesDPZvaiflerNJGlassockRJRosuvastatin: an independent analysis of risks and benefitsMed Gen Med2006873
   PubMedGoogle Scholar